Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
- PMID: 37197591
- PMCID: PMC10158041
- DOI: 10.1016/j.isci.2023.106802
Assessment of SARS-CoV-2 neutralizing antibody titers in breastmilk from convalescent and vaccinated mothers
Abstract
Breastmilk contains antibodies that could protect breastfed infants from infections. In this work, we examined if antibodies in breastmilk could neutralize SARS-CoV-2 in 84 breastmilk samples from women that were either vaccinated (Comirnaty, mRNA-1273, or ChAdOx1), infected with SARS-CoV-2, or both infected and vaccinated. The neutralization capacity of these sera was tested using pseudotyped vesicular stomatitis virus carrying either the Wuhan-Hu-1, Delta, or BA.1 Omicron spike proteins. We found that natural infection resulted in higher neutralizing titers and that neutralization correlated positively with levels of immunoglobulin A in breastmilk. In addition, significant differences in the capacity to produce neutralizing antibodies were observed between both mRNA-based vaccines and the adenovirus-vectored ChAdOx1 COVID-19 vaccine. Overall, our results indicate that breastmilk from naturally infected women or those vaccinated with mRNA-based vaccines contains SARS-CoV-2 neutralizing antibodies that could potentially provide protection to breastfed infants from infection.
Keywords: Health sciences; Immune response; Public health; Virology.
© 2023 The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.Int J Mol Sci. 2022 Jul 12;23(14):7675. doi: 10.3390/ijms23147675. Int J Mol Sci. 2022. PMID: 35887023 Free PMC article.
-
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14. Med. 2022. PMID: 35437520 Free PMC article.
-
Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.Vaccines (Basel). 2022 Oct 26;10(11):1807. doi: 10.3390/vaccines10111807. Vaccines (Basel). 2022. PMID: 36366316 Free PMC article.
-
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.Front Immunol. 2022 Sep 26;13:981693. doi: 10.3389/fimmu.2022.981693. eCollection 2022. Front Immunol. 2022. PMID: 36225911 Free PMC article.
-
SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.Front Immunol. 2023 Apr 25;14:1170759. doi: 10.3389/fimmu.2023.1170759. eCollection 2023. Front Immunol. 2023. PMID: 37180152 Free PMC article.
Cited by
-
Milk antibody response after 3rd COVID-19 vaccine and SARS-CoV-2 infection and implications for infant protection.iScience. 2023 Aug 29;26(10):107767. doi: 10.1016/j.isci.2023.107767. eCollection 2023 Oct 20. iScience. 2023. PMID: 37731614 Free PMC article.
-
Development and Concordance of Binding and Neutralizing Assays to Determine SARS-CoV-2 Antibody Activity in Human Milk.Pathog Immun. 2025 May 22;10(2):97-121. doi: 10.20411/pai.v10i2.799. eCollection 2025. Pathog Immun. 2025. PMID: 40475854 Free PMC article.
-
SARS-CoV-2 Antibody Profiles in Maternal Serum and Breast Milk Following mRNA COVID-19 Vaccination: A Longitudinal Prospective Observational Cohort Study.Vaccines (Basel). 2023 Oct 26;11(11):1643. doi: 10.3390/vaccines11111643. Vaccines (Basel). 2023. PMID: 38005975 Free PMC article.
-
Short-lived neutralizing activity against SARS-CoV-2 in newborns of immunized mothers.Pediatr Allergy Immunol. 2025 Apr;36(4):e70084. doi: 10.1111/pai.70084. Pediatr Allergy Immunol. 2025. PMID: 40202786 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous